Revenue (Annual)

Revenue: The sum of all revenue fields included for a company's operating activities.

Universe Pharmaceuticals INC (UPC) had Revenue of $23.02M for the most recently reported fiscal year, ending 2024-09-30.

Quarterly Annual

Figures for fiscal year ending 2024-09-30

Income Statement Financials
Revenue	$23.02M
Net Income	$-8.73M
Cost of Goods Sold	$16.95M
Gross Profit	$6.07M
Operating Expenses	$31.04M
Operating Income	$-8.02M
Non-Operating Income/Expense	$-0.10M
Pre-Tax Income	$-8.12M
Normalized Pre-Tax Income	$-8.12M
Income after Taxes	$-8.73M
Income from Continuous Operations	$-8.73M
Consolidated Net Income/Loss	$-8.73M
Normalized Income after Taxes	$-8.73M
EBIT	$-8.02M
EBITDA	$-7.53M
Weighted-Average Shares Outstanding (Basic)	0.01M
Weighted-Average Shares Outstanding (Diluted)	0.01M
Earnings per Share (EPS) (Basic)	$-626.96
Earnings per Share (EPS) (Diluted)	$-626.96
Balance Sheet Financials
Current Assets	$51.64M
Property, Plant, and Equipment	$3.57M
Long-Term Assets	$16.32M
Total Assets	$67.95M
Current Liabilities	$20.31M
Long-Term Debt	$2.14M
Long-Term Liabilities	$2.14M
Total Liabilities	$22.45M
Common Equity	$45.50M
Tangible Shareholders Equity	$45.24M
Shareholders Equity	$45.50M
Common Shares Outstanding	0.04M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-9.51M
Cash Flow from Investing Activities	$-0.36M
Cash Flow from Financial Activities	$33.95M
Beginning Cash	$5.29M
End Cash	$29.50M
Increase/Decrease in Cash	$24.21M
Stock-Based Compensation	--
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	2.54
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.04
Debt to Equity Ratio	0.18
Gross Margin	26.37%
Operating Margin	-34.83%
EBIT Margin	-34.83%
EBITDA Margin	-32.72%
Pre-Tax Profit Margin	-35.27%
Profit Margin	-37.90%
Free Cash Flow	$-9.75M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.34
Inventory Turnover	9.76
Receiveable Turnover	1.24
Days Sales in Receivables	294.42
Return on Equity	-19.18%
Return on Tangible Equity	-19.29%
Return on Assets	-12.84%
Return on Investments	-18.32%
Book Value Per Share	$1061.17
Free Cash Flow per Share	$-700.48
Operating Cash Flow per Share	$-682.95

Data from Zacks Investment Research, Inc.